References
1 Toorop, M. M. A., Chen, Q., Tichelaar, V., Cannegieter, S. C. & Lijfering, W. M. Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study. Eur Heart J 42 , 4126-4137, doi:10.1093/eurheartj/ehab421 (2021).
2 Escobar, C. et al. Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Clin Drug Investig 41 , 941-953, doi:10.1007/s40261-021-01091-w (2021).
3 Chen, S. T. & Patel, M. R. Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. Prog Cardiovasc Dis 60 , 514-523, doi:10.1016/j.pcad.2018.01.005 (2018).
4 Lip, G. Y. H. et al. Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med 289 , 42-52, doi:10.1111/joim.13140 (2021).
5 Gu, Z. C. et al. Left Atrial Appendage Thrombus Formation in a Patient on Dabigatran Therapy Associated With ABCB1 and CES-1 Genetic Defect. Front Pharmacol 9 , 491, doi:10.3389/fphar.2018.00491 (2018).
6 Ji, Q. et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. Br J Clin Pharmacol 87 , 2247-2255, doi:10.1111/bcp.14646 (2021).
7 Pare, G. et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127 , 1404-1412, doi:10.1161/CIRCULATIONAHA.112.001233 (2013).
8 Shi, J. et al. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.Biochem Pharmacol 119 , 76-84, doi:10.1016/j.bcp.2016.09.003 (2016).
9 Sychev, D. et al. Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease. Drug Metab Pers Ther 35 , doi:10.1515/dmpt-2019-0029 (2020).
10 Sychev, D. A. et al. Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. Mol Biol Rep 46 , 2761-2769, doi:10.1007/s11033-019-04722-w (2019).
11 Zubiaur, P. et al. Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. Adv Ther 37 , 3537-3550, doi:10.1007/s12325-020-01414-x (2020).
12 Liu, Y. et al. The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects.Pharmgenomics Pers Med 14 , 477-485, doi:10.2147/PGPM.S291723 (2021).
13 Dimatteo, C. et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res 144 , 1-5, doi:10.1016/j.thromres.2016.05.025 (2016).
14 Zhu, Z. et al. Dabigatran plasma concentration indicated the risk of patients with non-valvular atrial fibrillation. Heart Vessels , doi:10.1007/s00380-021-01974-0 (2021).
15 Hori, M. et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 44 , 1891-1896, doi:10.1161/STROKEAHA.113.000990 (2013).
16 Raymond, J. et al. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J Pers Med 11 , doi:10.3390/jpm11010037 (2021).
17 Wu, T., Xia, X., Fu, J., Chen, W. & Zhang, J. Left atrial appendage thrombus formation in a patient with atrial fibrillation on dabigatran therapy associated with CES1 and ABCB1 genetic polymorphisms: A case report. Medicine (Baltimore) 99 , e22084, doi:10.1097/MD.0000000000022084 (2020).
18 Rosian, A. N. et al. An Exploratory Association Analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban.J Pers Med 10 , doi:10.3390/jpm10030133 (2020).
19 Sychev, D. A. et al. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmgenomics Pers Med 11 , 127-137, doi:10.2147/PGPM.S169277 (2018).
20 Lahteenmaki, J. et al. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users. Clin Pharmacol Ther 110 , 768-776, doi:10.1002/cpt.2316 (2021).